Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Kaleido Biosciences (optimizing the human microbiome to treat disease) raised $101mm through its Series C round. Founding investor Flagship Pioneering participated, along with a subsidiary of the Abu Dhabi Investment Authority, Fidelity Management & Research, Invus, and Rock Springs Capital.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?